Moffitt begins 2013 with two new programs, Cancer Biology & Evolution and Chemical Biology & Molecular Medicine.
Over the last few years, the Molecular Oncology & Drug Discovery (MODD) Program developed an increasing emphasis on research in the areas of tumor evolution, the microenvironment, mathematical modeling and tumor ecology. The Center’s mathematicians have played an important role in leading this new direction. At the same time, breakthroughs in genomics and personalized medicine led to the structural biologists and chemists in the program to increasingly work closely with members of the Experimental Therapeutics program on drug development and on systems level views of pathways and drugs. Due to these evolving interests, the time came to reorganize these two programs around these new themes. Therefore, the MODD Program has evolved into the Cancer Biology & Evolution Program and the Experimental Therapeutics Program has evolved into the Chemical Biology & Molecular Medicine Program.
The initial goal of the Cancer Biology & Evolution Program (CBE) is to generate and integrate fundamental knowledge on processes that underlie the evolution of cancer. Initially, the program aims to:
Cancer Biology and Evolution Program Members
Robert Gatenby, MD
Mark Alexandrow, PhD
Alexander Anderson, PhD
David Basanta, PhD
Gregory C. Bloom, PhD
Srikumar Chellappan, PhD
Jin Q. Cheng, MD, PhD
- Understand interactions between the intra- and extra-cellular regulatory components of biological systems and how normal interactions are modified to give rise to malignant states.
- Identify drivers of tumor evolution and metastasis.
- Apply novel approaches to understanding of tumor growth and metastasis through systematic data integration and modeling.